Neuland Laboratories Quarterly Results for Trading Insights
In Mar 2026, Neuland Laboratories (NEULANDLAB) reported revenue ₹789 Cr and net profit ₹213 Cr — revenue +134.8% YoY. Browse NEULANDLAB annual financials for revenue, profit, balance sheet and cash flow data.
NEULANDLAB Quarterly Results — Revenue, Profit & EPS Highlights
Neuland Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Neuland Laboratories stock price NSE.
- Revenue of ₹789 Cr in Mar 2026 (+52.9% vs Sept 2025, +134.8% vs Mar 2025)
- Net Profit of ₹213 Cr in Mar 2026 (+119.6% vs Sept 2025, +660.7% vs Mar 2025)
- EBITDA of ₹320 Cr in Mar 2026 (+103.8% vs Sept 2025)
- Operating Margin of 40.0% in Mar 2026 (+10.0pp vs Sept 2025)
- Earnings Per Share of ₹165.76 in Mar 2026 (+119.6% vs Sept 2025)
Neuland Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NEULANDLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 789 | 516 | 336 | 301 | 448 | 52.9% | 134.8% |
| Net Profit (₹ Cr) | 213 | 97 | 28 | 14 | 41 | - | - |
| EBITDA (₹ Cr) | 320 | 157 | 59 | 42 | 85 | - | - |
| EPS (₹) | 165.76 | 75.49 | 21.67 | 10.83 | 31.62 | - | - |
| Operating Margin (%) | 40.0% | 30.0% | 16.0% | 12.0% | 18.0% | - | - |
NEULANDLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Neuland Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore NEULANDLAB stock price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NEULANDLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Neuland Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores